Recro Pharma (REPH) Tops Q4 EPS by 17c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus

Recro Pharma (NASDAQ: REPH) reported Q4 EPS of ($0.58), $0.17 better than the analyst estimate of ($0.75). Revenue for the quarter came in at $17.78 million versus the consensus estimate of $16.05 million.

“As we await the upcoming review decision from the U.S. Food and Drug Administration (FDA) for intravenous (IV) meloxicam, we are building our commercial infrastructure and preparing for our first potential product launch during 2019,” said Gerri Henwood, President and Chief Executive Officer of Recro Pharma. “For the Gainesville CDMO division, we achieved another record year generating 2018 annual revenue of $77.3 million, 8% higher than in 2017. As we look ahead to 2019, we expect to see continued strong performance from our manufacturing business, providing significant non-dilutive capital.”

GUIDANCE:

Recro Pharma sees FY2019 revenue of $80 million, versus the consensus of $88.68 million.

For 2019, the Company expects revenue generated from its CDMO division to be approximately $80 million, taking into consideration existing contracts and timing of customer order patterns, as well as our experience with customer’s product market estimations.

For earnings history and earnings-related data on Recro Pharma (REPH) click here.

You May Also Be Interested In

• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• MiniMed ships its Flex pump with Abbott's Instinct sensor in the U.S.
• Aon names interim CFO as Edmund Reese exits the firm